Gerardo Garcia-Gonzalez

Dr. Gerardo Garcia-Gonzalez

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Molecular Immunology
Verified
Journal Article
Closed access
Gerardo Garcia-GonzalezGerardo Garcia-Gonzalez
Gerardo Garcia-Gonzalez
ASAlejandro Sanchez
Alejandro Sanchez
RHRomel Hernández-Bello
Romel Hernández-Bello
GGGloria M. González
Gloria M. González
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
JPJosé Prisco Palma-Nicolás
José Prisco Palma-Nicolás

20 August 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DEDavid Encinas-Basurto
David Encinas-Basurto
PMPatricia Dolores Martinez-Flores
Patricia Dolores Martinez-Flores
JGJoselyn García
Joselyn García
MMMARCO ANTONIO LÓPEZ MATA
MARCO ANTONIO LÓPEZ MATA
Gerardo Garcia-GonzalezGerardo Garcia-Gonzalez
Gerardo Garcia-Gonzalez
JJJosué Juarez
Josué Juarez
The concerning increase in respiratory infections that are resistant to multiple drugs has led to a growing interest in bacteriophage therapy as a potential alternative to conventional antibiotics. Effective phage delivery to the lungs, however, presents several formulation and stability issues, particularly for inhalation-based methods. This review highlights current developments in the creation of dry powder formulations that can be inhaled for pulmonary phage therapy, with a focus on encapsulation methods based on nanoparticles, such as solid lipid nanoparticles (SLNs) and polymer-based nanoparticles. These carriers enhance the aerodynamic characteristics of phages, making them suitable for deep lung deposition, while also protecting them during processing and storage. Several drying methods have been investigated to create powders with optimal morphologies, porosity, and dispersibility, including spray drying and spray freeze drying. The review also emphasizes how the phage morphotype affects stability, especially when nebulization stress is present. Furthermore, the advantages of nanoparticle matrices are confirmed by the reduced viability loss (usually< 0.5 log PFU) of encapsulated phages. Standardizing production processes, scaling up, and ensuring regulatory compliance remain challenging despite encouraging preclinical results. The combination of phage therapy with nanotechnology creates new avenues for the utilization of inhalable delivery methods to treat multidrug-resistant pulmonary infections. To translate these novel formulations from preclinical development to clinical application, sustained multidisciplinary collaboration across pharmaceutical sciences, microbiology, and clinical pharmacology is essential.

21 June 2025 in Current Fungal Infection Reports
Verified
Journal Article
Closed access
PDF file
Gerardo Garcia-GonzalezGerardo Garcia-Gonzalez
Gerardo Garcia-Gonzalez
GGGloria M. González
Gloria M. González
ABAlexandro Bonifaz
Alexandro Bonifaz

27 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PMPatricia Dolores Martinez-Flores
Patricia Dolores Martinez-Flores
JGJoselyn Aime García-Mar
Joselyn Aime García-Mar
JGJose Manuel García-Perez
Jose Manuel García-Perez
DEDavid Encinas-Basurto
David Encinas-Basurto
Gerardo Garcia-GonzalezGerardo Garcia-Gonzalez
Gerardo Garcia-Gonzalez
JJJosué Juarez
Josué Juarez
Background/Objectives: The quest for effective therapeutic alternatives for infec-tions caused by multidrug-resistant (MDR) bacteria remains a major global health priority. In this context, bacteriophage therapy has re-emerged as a promising strate-gy due to its high host specificity and ability to infect and lyse targeted bacterial strains. However, clinical translation is limited by biological and technological chal-lenges, including phage instability and rapid inactivation after administration. Algi-nate- and chitosan-based polymeric nanomatrices offer a practical way to address these limitations. Properly engineered nanoparticles can improve phage stability, protect against environmental stressors, reduce inactivation, and enable localized, controlled release at the infection site. Methods: A polysaccharide-based nanocarrier composed of hydrophobically modified alginate (mAlg) and chitosan was developed. Encapsulation of bacteriophage vB_Eco_K-02 within mAlg-Cs nanoparticles was achieved by ultrasonication-assisted polyelectrolyte complexation. Particle size, ζP, and morphology were evaluated, and phage encapsulation efficiency and antibacte-rial activity were assessed in vitro. Results: The mAlg-Cs formulation at a 1:0.625 mass ratio yielded nanoparticles with the most favorable physicochemical properties, including improved size distribution, high colloidal stability, and regular morphology. vB_Eco_K-02-loaded NPs (mAlg-Cs-Phg) achieved a high encapsulation efficiency (99 %) and preserved lytic activity after formulation, resulting in strong inhibition of E. coli growth in kinetic assays. Conclusions: mAlg-Cs nanoparticles provide an effi-cient platform for encapsulating vB_Eco_K-02 while preserving phage infectivity and enabling effective antibacterial activity. This nanosystem represents a promising strategy to enhance phage delivery for the treatment of bacterial infection.

14 January 2026 in Food Biophysics
Verified
Journal Article
Closed access
PDF file
IGIldefonso Guerrero-Encinas
Ildefonso Guerrero-Encinas
Silvia Elena Burruel IbarraSilvia Elena Burruel Ibarra
Silvia Elena Burruel Ibarra
LCLuis Quihui Cota
Luis Quihui Cota
JJJosué Juarez
Josué Juarez
EVEdith Valbuena-Gregorio
Edith Valbuena-Gregorio
MMMARCO ANTONIO LÓPEZ MATA
MARCO ANTONIO LÓPEZ MATA

22 April 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
PMPatricia Dolores Martinez-Flores
Patricia Dolores Martinez-Flores
MCMARISOL GASTELUM CABRERA
MARISOL GASTELUM CABRERA
Manuel Gerardo Ballesteros-MonrrealManuel Gerardo Ballesteros-Monrreal
Manuel Gerardo Ballesteros-Monrreal
Pablo Mendez-PfeifferPablo Mendez-Pfeiffer
Pablo Mendez-Pfeiffer
MMMARCO ANTONIO LÓPEZ MATA
MARCO ANTONIO LÓPEZ MATA
JJJosué Juarez
Josué Juarez
Background/Objectives: Bacterial infections remain among the top ten major public health concerns, contributing to a high number of incidences of disease and mortality worldwide, exacerbated by the rise of multidrug-resistant bacteria (MDRB). Consequently, it is crucial to develop novel antimicrobial strategies, including the use of functional nanoparticles. Gold nanoparticles (GNPs) have emerged as promising candidates due to their unique optical properties, particularly their ability to efficiently convert absorbed light into heat through the photothermal (PT) effect, which can be harnessed for bacteria eradication. Methods: Chitosan was modified with 3-mercaptopropionic acid to introduce sulfur groups, facilitating gold deposition onto chitosan nanoparticle (TCNPs) surface. The gold shell was subsequently formed via a seed-mediated method, wherein gold seeds were adsorbed onto TCNPs and further grown to form the shell. Photothermal effect on the bacterial viability was evaluated. Results: TCNPs with a size of 178 nm and spherical morphology were obtained. After the gold shell (TCNP@Au) exhibited a photothermal conversion efficiency of 31%, making them a promising photothermal agent for bacterial clearance. Notably, the viability of Escherichia coli was significantly reduced in the presence of TCNP@Au and was almost eradicated upon PT treatment. In contrast, TCNP@Aus were non-toxic for Staphylococcus aureus. Conclusions: TCNP@Au demonstrated favorable photothermal properties, presenting a novel nanoplatform for antibacterial applications, particularly against Gram-negative bacteria. However, further investigation is required to optimize the PT-based strategies against Gram-positive bacteria, such as S. aureus.